(Q31140133)

English

Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

0 references

Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Yu Liu

1

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Tie-Jun Yin

2

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Rong Zhou

3

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Si Zhou

4

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Liang Fan

5

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Rong-Ge Zhang

6

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

publication date

26 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

72

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

1125-1132

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Optimizing first-line treatment options for patients with advanced NSCLC.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Updated clinical information on multitargeted antifolates in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Biological prognostic and predictive factors in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Practical methods for incorporating summary time-to-event data into meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Correlation between thymidylate synthase protein expression and gene polymorphism with clinicopathological parameters in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

A genomic view of mosaicism and human disease

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2299-2

21 January 2018

Identifiers

10.1007/S00280-013-2299-2

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31140133&oldid=2195103437"